Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AVNS Stock Forecast 2026-2027
$24.96
Current Price
$1.17B
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to AVNS Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
AVNS Price Momentum
+0.1%
1 Week Change
+0.4%
1 Month Change
+114.4%
1 Year Change
+122.3%
Year-to-Date Change
-2.1%
From 52W High of $25.49
+168.3%
From 52W Low of $9.30
📊 TOP ANALYST CALLS
Did AVNS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Avanos is one of their latest high-conviction picks.
Latest AVNS Stock Price Targets & Analyst Predictions
AVNS has shown a year-to-date change of 122.3% and a 1-year change of 114.4%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for AVNS. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AVNS Analyst Ratings
0
Buy
1
Hold
0
Sell
AVNS Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $24.96
Latest AVNS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AVNS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 7, 2024 | JMP Securities | Daniel Stauder | Market Perform | Reiterates | $N/A |
| Jul 25, 2023 | Keybanc | Sector Weight | Downgrade | $N/A | |
| Jun 21, 2023 | Stifel | Hold | Reiterates | $N/A | |
| May 22, 2023 | CL King | Buy | Initiates | $N/A | |
| May 4, 2023 | Morgan Stanley | Underweight | Maintains | $N/A | |
| Feb 22, 2023 | Morgan Stanley | Underweight | Maintains | $N/A | |
| Jan 6, 2023 | Morgan Stanley | Underweight | Maintains | $N/A | |
| Nov 3, 2022 | Keybanc | Overweight | Maintains | $N/A | |
| Oct 11, 2022 | Morgan Stanley | Underweight | Maintains | $N/A | |
| Aug 10, 2022 | Keybanc | Overweight | Maintains | $N/A | |
| Jul 18, 2022 | Stifel | Hold | Maintains | $N/A | |
| Jul 15, 2022 | Morgan Stanley | Underweight | Maintains | $N/A | |
| May 5, 2022 | Morgan Stanley | Underweight | Maintains | $N/A | |
| Feb 24, 2022 | Keybanc | Overweight | Maintains | $N/A | |
| Jan 7, 2022 | Morgan Stanley | Underweight | Maintains | $N/A | |
| Aug 4, 2021 | Morgan Stanley | Underweight | Maintains | $N/A | |
| Aug 4, 2021 | Stephens & Co. | Equal-Weight | Downgrade | $N/A | |
| Aug 4, 2021 | Keybanc | Overweight | Maintains | $N/A | |
| Jan 8, 2021 | KeyBanc | Overweight | Maintains | $N/A | |
| Jan 8, 2021 | Keybanc | Paul Knight | Overweight | Maintains | $55.00 |
Avanos Medical Inc. (AVNS) Competitors
The following stocks are similar to Avanos based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Avanos Medical Inc. (AVNS) Financial Data
Avanos Medical Inc. has a market capitalization of $1.17B with a P/E ratio of 34.4x. The company generates $715.90M in trailing twelve-month revenue with a -10.4% profit margin.
Revenue growth is +8.8% quarter-over-quarter, while maintaining an operating margin of +5.4% and return on equity of -9.2%.
Valuation Metrics
Market Cap
$1.17B
Enterprise Value
$1.24B
P/E Ratio
34.4x
PEG Ratio
-1.6x
Price/Sales
1.6x
Growth & Margins
Revenue Growth (YoY)
+8.8%
Gross Margin
+51.7%
Operating Margin
+5.4%
Net Margin
-10.4%
EPS Growth
-22.7%
Financial Health
Cash/Price Ratio
+5.6%
Current Ratio
2.5x
Debt/Equity
17.7x
ROE
-9.2%
ROA
+1.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Avanos Medical Inc. (AVNS) Business Model
About Avanos Medical Inc.
What They Do
Develops medical devices for patient care improvement.
Business Model
Avanos Medical generates revenue by designing and manufacturing a diverse array of medical devices focused on chronic care and pain management. Their products, including enteral feeding systems and respiratory therapy equipment, are sold to hospitals, outpatient facilities, and home care providers, enhancing patient care while reducing costs.
Additional Information
The company emphasizes innovation and responsiveness to healthcare providers' needs, positioning itself as a key player in improving patient outcomes and operational efficiency within the medical industry.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
2,287
CEO
Mr. David C. Pacitti M.B.A.
Country
United States
IPO Year
2018
Website
avanos.comAvanos Medical Inc. (AVNS) Latest News & Analysis
Latest News
Quick Summary
Avanos Medical, Inc. has received all necessary regulatory approvals to proceed with its acquisition by affiliates of American Industrial Partners.
Why It Matters
Regulatory approval for Avanos Medical's acquisition by AIP signals a significant corporate restructuring, potentially impacting stock performance and strategic direction.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Kahn Swick & Foti, LLC is investigating the proposed sale of Avanos Medical (NYSE: AVNS) to American Industrial Partners, offering $25.00 per share to shareholders.
Why It Matters
The investigation into Avanos Medical's sale may indicate potential issues with the acquisition process or valuation, impacting shareholder confidence and stock price volatility.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
AVNS is experiencing growth from SNS momentum, Nexus Medical integration, and the AIP deal, but faces challenges from tariff costs, margin pressure, and weakness in PM&R.
Why It Matters
AVNS shows growth potential through new deals and integrations, but rising costs and market weaknesses could impact profitability, influencing investor sentiment and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Avanos Medical (AVNS) recently reported earnings 30 days ago. Investors should monitor upcoming developments and market reactions for future stock performance.
Why It Matters
Earnings reports can impact stock performance and investor sentiment. AVNS's recent earnings results may indicate future growth potential or challenges, influencing investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
New Strong Sell Stocks for May 15th
2 months ago
Quick Summary
AVNS, BKR, and CAG have been assigned a Zacks Rank #5 (Strong Sell) as of May 15, 2026.
Why It Matters
AVNS, BKR, and CAG receiving a Zacks Rank #5 signals potential underperformance, prompting investors to reassess their positions and risk exposure.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Avanos Medical's international revenue trends are influencing Wall Street forecasts, impacting future stock performance. Investors should monitor these developments closely.
Why It Matters
Avanos Medical's international revenue trends can influence earnings forecasts, affecting stock performance and investor sentiment regarding future growth potential and market expansion.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Frequently Asked Questions About AVNS Stock
What is Avanos Medical Inc.'s (AVNS) stock forecast for 2027?
Analyst forecasts for Avanos Medical Inc. (AVNS) are not currently available. The stock is trading at $24.96.
Is AVNS stock a good investment in 2027?
According to current analyst ratings, AVNS has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $24.96. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AVNS stock?
Price predictions from Wall Street analysts for AVNS are not currently available. The stock is trading at $24.96.
What is Avanos Medical Inc.'s business model?
Avanos Medical generates revenue by designing and manufacturing a diverse array of medical devices focused on chronic care and pain management. Their products, including enteral feeding systems and respiratory therapy equipment, are sold to hospitals, outpatient facilities, and home care providers, enhancing patient care while reducing costs.
What is the highest forecasted price for AVNS Avanos Medical Inc.?
Price targets from Wall Street analysts for AVNS are not currently available. The stock is trading at $24.96.
What is the lowest forecasted price for AVNS Avanos Medical Inc.?
Price targets from Wall Street analysts for AVNS are not currently available. The stock is trading at $24.96.
What is the overall AVNS consensus from analysts for Avanos Medical Inc.?
The overall analyst consensus for AVNS is neutral. Out of 3 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are AVNS stock price projections?
Stock price projections, including those for Avanos Medical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 2:08 AM UTC